These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [A dynamic study on titer of EB virus VCA/IgA and EA/IgA in nasopharygeal carcinoma patients]. Ji MF, Guo YQ, Liang JS, Zheng SA, Cheng WM, Yu BH, Ou XT, Wang DK. Zhonghua Zhong Liu Za Zhi; 2003 May; 25(3):243-5. PubMed ID: 12839685 [Abstract] [Full Text] [Related]
9. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Tsang RK, Vlantis AC, Ho RW, Tam JS, To KF, van Hasselt CA. Head Neck; 2004 Jul; 26(7):598-602. PubMed ID: 15229902 [Abstract] [Full Text] [Related]
10. Epstein-Barr virus serological markers for nasopharyngeal carcinoma in Thailand. Puthavathana P, Sutthent R, Vitavasiri A, Wasi C, Chantarakul N, Thongcharoen P. Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):326-31. PubMed ID: 1818381 [Abstract] [Full Text] [Related]
12. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, Chao J, Jin YT, Lin JC. Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):130-7. PubMed ID: 16979842 [Abstract] [Full Text] [Related]
13. [Nasopharyngeal carcinoma (NPC) mortality rate in two districts of Guangdong Province and their relation to IgA antibody level against EB virus capsid antigen]. Zong YS. Zhonghua Zhong Liu Za Zhi; 1992 Mar 01; 14(2):103-5. PubMed ID: 1319889 [Abstract] [Full Text] [Related]
14. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Shao JY, Huang XM, Yu XJ, Huang LX, Wu QL, Xia JC, Wang HY, Feng QS, Ren ZF, Ernberg I, Hu LF, Zeng YX. Anticancer Res; 2001 Mar 01; 21(4B):3021-9. PubMed ID: 11712805 [Abstract] [Full Text] [Related]
16. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM. J Med Virol; 2005 Apr 01; 75(4):593-602. PubMed ID: 15714486 [Abstract] [Full Text] [Related]
17. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx]. Mazeron MC. Bull Cancer Radiother; 1996 Apr 01; 83(1):3-7. PubMed ID: 8679277 [Abstract] [Full Text] [Related]
18. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Liu MT, Yeh CY. Radiat Med; 1998 Apr 01; 16(2):113-7. PubMed ID: 9650898 [Abstract] [Full Text] [Related]
19. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen. Mo WN, Tang AZ, Zhou L, Huang GW, Wang Z, Zeng Y. Chin Med J (Engl); 2009 May 20; 122(10):1173-8. PubMed ID: 19493466 [Abstract] [Full Text] [Related]
20. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Chang KP, Hsu CL, Chang YL, Tsang NM, Chen CK, Lee TJ, Tsao KC, Huang CG, Chang YS, Yu JS, Hao SP. Oral Oncol; 2008 Aug 20; 44(8):784-92. PubMed ID: 18206420 [Abstract] [Full Text] [Related] Page: [Next] [New Search]